AEterna's CEO, CBO resign
David Mazzo announced that he's resigning from AEterna Zentaris after exactly one year as CEO. Reasons for the move were not disclosed. Board chairman Juergen Ernst will serve as interim President and CEO until a replacement can be found. Senior VP and chief business officer Ellen McDonald also resigned--no word yet on who will replace her. Both resignations take effect immediately.
Additionally, the company said that it will look to sell additional non-core assets as a source of non-dilutive funding.
- read the release
ALSO: Pharmacopeia's CEO Leslie Browne has resigned in order to pursue other interests. His resignation was effective April 9. Release
Related Articles:
AEterna files iNDA. Aeterna report
AEterna Zentaris announces ZEN-012 data. AEterna report
AEterna regains rights to Cetrorelix. AEterna report
Be the first to comment
More stories about Cetrorelix AEterna Zentaris David Mazzo Juergen Ernst Ellen McDonald Pharmacopeia Leslie Browne
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets